

From: Dr Hashim Al-Hashimi, Ph.D. hashim.al.hashimi@duke.edu
Subject: Re: Potential Contribution for Book Chapter on RNA Therapeutics
Date: December 9, 2017 at 2:17 PM
To: Garner, Amanda algarner@med.umich.edu
Cc: Dr Hashim Al-Hashimi, Ph.D. hashim.al.hashimi@duke.edu, Laura Ganser laurganser@gmail.com



great tks Amanda !

Hashim M Al-Hashimi

James B. Duke Professor of Biochemistry
Director, Duke Center for RNA Biology
Department of Biochemistry
Department of Chemistry
Duke University School of Medicine
Duke University
Office 228-B Nanaline H Duke Building
Office Tel: 919-660-1113 Lab Tel: 919-660-1114/5/6

Office mailing Address:
Box 3711
Nanaline H. Duke Building
307 Research Drive
Durham NC 27710

Lab mailing address:
Duke Medical Research Center
307 Research Dr., Box 3711
Nanaline Duke Bldg, RM 227
Durham, NC 27710-3025

On Dec 9, 2017, at 1:59 PM, Garner, Amanda <algarner@med.umich.edu> wrote:

Hi Hashim,

Yes, it is ok for you to include this statement.

Best,
Amanda

Amanda L. Garner, Ph.D.
Assistant Professor
College of Pharmacy
Department of Medicinal Chemistry
University of Michigan
NCRC B520/1362
1600 Huron Parkway
Ann Arbor, MI 48109
Phone: (734) 763-2654
Lab Website: www.garnerlaboratory.com

From: "Dr Hashim Al-Hashimi, Ph.D." <hashim.al.hashimi@duke.edu>
Date: Saturday, December 9, 2017 at 8:52 AM
To: Amanda Garner <algarner@med.umich.edu>
Cc: "Dr Hashim Al-Hashimi, Ph.D." <hashim.al.hashimi@duke.edu>, Laura Ganser <laurganser@gmail.com>
Subject: Re: Potential Contribution for Book Chapter on RNA Therapeutics

Hi Amanda -

Thanks very much for all help! We would like to mention in our revised manuscript that our hits were inactive in your HTS - since your paper is not yet published, we wanted to refer to it as a personal communication. According to the NSMB journal guidelines "*If the manuscript includes personal communications, please provide a written statement of permission from any person who is quoted. E-mail permission messages are acceptable.*"

We would like to include one statement that refers to your screen as shown below -

"The anthraquinone molecules (CCG-133868, CCG-133879, CCG-133895, CCG-133905 and CCG-133994) show selectivity relative to tRNA (Table 1) and insignificant activity in a recent HTS targeting a microRNA-protein interaction (Dr. A.L. Garner University of Michigan, personal communication)."

You can grant permission by simply replying to this email granting the permission.

It would not be a problem at all if you preferred that we not reference your screen - we would then omit any reference to it - this is not critical for our manuscript - we felt that it would both be responsive to one of the reviewer's criticism while also helping elevate the standard in the field by emphasizing the importance of cross-screening.

With best wishes,
Hashim

Hashim M Al-Hashimi

James B. Duke Professor of Biochemistry
Director, Duke Center for RNA Biology
Department of Biochemistry
Department of Chemistry
Duke University School of Medicine
Duke University
Office 228-B Nanaline H Duke Building
Office Tel: 919-660-1113 Lab Tel: 919-660-1114/5/6

Office mailing Address:
Box 3711
Nanaline H. Duke Building
307 Research Drive
Durham NC 27710

Lab mailing address:

Duke Medical Research Center
307 Research Dr., Box 3711
Nanaline Duke Bldg, RM 227
Durham, NC 27710-3025

On Nov 25, 2017, at 12:23 PM, Garner, Amanda <algarner@med.umich.edu> wrote:

Hi Hashim and Laura,

The paper is about our Dicer assay; the Lin28 work has not yet been published as we are following up on a lead hit.

Here is what I can tell you about each of your hits:

CCG-133868: 16.4% inhibition against let-7/Lin28; not tested in the Dicer assay
CCG-133879: 16.6% inhibition against let-7/Lin28; not tested in the Dicer assay
CCG-133895: <5% inhibition against let-7/Lin28; not tested in the Dicer assay
CCG-133994: <5% inhibition against let-7/Lin28; not tested in the Dicer assay
CCG-133905: <5% inhibition against let-7/Lin28; not tested in the Dicer assay

If you would like us to test any compounds against the Dicer assay, please let me know and we would be happy to do so. I will also keep you in mind in the future for testing against TAR. Right now, all of our best hits from our screens target the proteins (which is not unexpected). But we also screened David's natural product extracts and know we have some RNA binders that need to be further purified.

Best,
Amanda

Amanda L. Garner, Ph.D.
Assistant Professor
College of Pharmacy
Department of Medicinal Chemistry
University of Michigan
NCRC B520/1362
1600 Huron Parkway
Ann Arbor, MI 48109
Phone: (734) 763-2654
Lab Website: www.garnerlaboratory.com

From: "Dr Hashim Al-Hashimi, Ph.D." <hashim.al.hashimi@duke.edu>

Date: Tuesday, November 21, 2017 at 5:09 PM

To: "Garner, Amanda" <algarner@med.umich.edu>

Cc: Laura Ganser <laurganser@gmail.com>

Subject: Re: Potential Contribution for Book Chapter on RNA Therapeutics

133868

Electronic Mail is not secure, may not be read every day, and should not be used for urgent or sensitive issues

Electronic Mail is not secure, may not be read every day, and should not be used for urgent or sensitive issues